Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron | B3 | Healthcare | Biotechnology & Medical Research | R$351.72B | 13.6x | 1.3 | R$55.72 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings BDR | B3 | Healthcare | Biotechnology & Medical Research | R$155.21B | 19.8x | 6.77 | R$220 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beigene | B3 | Healthcare | Biotechnology & Medical Research | R$153.94B | -44.4x | -1.39 | R$56 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | B3 | Healthcare | Biotechnology & Medical Research | R$139.97B | -31.3x | 0.18 | R$36.06 | -3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | B3 | Healthcare | Biotechnology & Medical Research | R$59.53B | -2.8x | -0.11 | R$7.99 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma AS | B3 | Healthcare | Biotechnology & Medical Research | R$54.87B | -22.1x | -0.92 | R$54.36 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioTechne | B3 | Healthcare | Biotechnology & Medical Research | R$47.63B | 50.9x | -1.71 | R$9.88 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomm On | B3 | Healthcare | Biotechnology & Medical Research | R$1.19B | -14.9x | -0.45 | R$9.38 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |